iCeutica, Inc today announced its sale to long-term partner Iroko (see iCeutica Media release).
Yuuwa Investment Director Dr James Williams conceived the iCeutica opportunity in 2004 as a potential business focused on improving the bioavailability of both new and approved drugs using a novel nanotechnology platform. Following a brief proof of concept study conducted in collaboration with the University of Western Australia, and filing of initial patent applications, iCeutica was co-founded in 2005 by James Williams and fellow Yuuwa Investment Director Liddy McCall, alongside iCeutica’s founding CEO Matthew Callahan.
Prior to founding Yuuwa Capital, both Liddy McCall and James Williams held, at various times, both Executive Management and Non-Executive Director roles in iCeutica.
The iCeutica case study is illustrative of the approach Yuuwa Capital takes to its early stage investments. Engagement by the Yuuwa team was pre-business plan and pre-patent filing – indeed James Williams is an inventor on the cornerstone iCeutica patent application. The result of this is a very successful business opportunity that has now yielded 10X return on value at the time of first financial investment.
Yuuwa Capital was established to reproduce this model by leveraging both early stage start-up skills and experience and applying its capital at the first (and subsequent) rounds of financing.
Press Release iCeutica sale to Iroko